Sagimet Biosciences Inc. Series A

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SGMT and other ETFs, options, and stocks.

About SGMT

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). 

CEO
David A. Happel
CEODavid A. Happel
Employees
14
Employees14
Headquarters
San Mateo, California
HeadquartersSan Mateo, California
Founded
2006
Founded2006
Employees
14
Employees14

SGMT Key Statistics

Market cap
104.63M
Market cap104.63M
Price-Earnings ratio
-1.81
Price-Earnings ratio-1.81
Dividend yield
Dividend yield
Average volume
366.24K
Average volume366.24K
High today
$3.37
High today$3.37
Low today
$3.11
Low today$3.11
Open price
$3.30
Open price$3.30
Volume
355.89K
Volume355.89K
52 Week high
$7.38
52 Week high$7.38
52 Week low
$1.73
52 Week low$1.73

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own SGMT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.